Lexeo Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Lexeo Therapeutics with a Buy rating and $22 price target. Lexeo is a clinical stage biotech company focused on the treatment of genetically-defined cardiovascular and central nervous system diseases using one-time gene therapies, the analyst tells investors in a research note. The firm says the company currently has multiple programs in development across rare cardiovascular disease and Alzheimer’s disease, with three important data catalysts upcoming in 2024. It likes the stock’s risk/reward for these catalysts, with potential upside to shares “if any of these datasets are positive.”